Fc-engineering for improved cancer immunotherapy.

Authors

Ella Borgman, Camille Le Gall, Hidde Ploegh, Novalia Pishesha

Published in

Biochemical Society transactions. Volume 54. Issue 8. Pages 1117-1130. Aug 26, 2026.

Abstract

Monoclonal antibodies have revolutionized cancer therapy, with approved therapeutics belonging predominantly to the immunoglobulin G (IgG) class. These IgGs mediate antitumor effects predominantly through engagement of Fcγ receptors on immune cells. This engagement results in therapy-activating Fc effector functions such as antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. Limitations nonetheless include suboptimal effector engagement and adverse immunological side effects. These drawbacks have driven the search for and optimization of Fc-engineering strategies, including Fc mutations, glycan modification, and choice of Ig isotype, to enhance therapeutic efficacy and tailor immune interactions.

PMID:
42621748
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.